Boston Medical Group

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Retrieved on: 
Monday, October 30, 2023
Vitiligo, Pigment, Boston Medical Group, Pharmacokinetics, Skin, Tolerability, Autoimmune disease, BET, Safety, Initiate, Therapy, Depigmentation, Patient, Pharmaceutical industry, Vaccine

The Phase 1b trial is a 16-week open-label trial assessing the safety, tolerability and pharmacokinetics of once-daily topical VYN201 in 29 patients across three dose cohorts (0.5%, 1.0% and 2.0% strengths).

Key Points: 
  • The Phase 1b trial is a 16-week open-label trial assessing the safety, tolerability and pharmacokinetics of once-daily topical VYN201 in 29 patients across three dose cohorts (0.5%, 1.0% and 2.0% strengths).
  • “We are encouraged by these data from our Phase 1b trial that demonstrate proof-of-concept in nonsegmental vitiligo, which we believe is the first clinical evidence of a BET inhibitor’s effect in autoimmune disease.
  • VYNE management will review the final results from the Phase 1b trial for VYN201.
  • The VYNE team will also discuss the Company’s development plans for VYN201 and its oral BET inhibitor VYN202.

Mirion Announces Departure of Medical Group President

Retrieved on: 
Wednesday, October 18, 2023
Health, Other Science, Energy, Radiology, Research, Science, Nuclear, Boston Medical Group, NYSE, MIR

Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named.

Key Points: 
  • Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named.
  • Mr. Logan had previously served as acting Medical Group President through much of 2022.
  • “Mike has been a valued member of the Mirion executive team for the last year, and we are grateful for his contributions,” said Mr. Logan.
  • “All of us at Mirion wish Mike well as he takes this next step in his career as a public company CEO.”

Vancouver Clinic Earns Therapeutic License to Administer New Drug to Treat Prostate Cancer

Retrieved on: 
Tuesday, March 7, 2023
Nuclear medicine, RLT, Life, Prostate cancer, Travel, Death, Radiation, University of Toronto Faculty of Medicine, Canadian Nuclear Safety Commission, Patient, Cancer, Clinical, Health, University, Lions Gate Hospital, Radiopharmaceutical, Faculty, Health Canada, Beta, Boston Medical Group, Dairy, Pharmaceutical industry, Medical imaging, Medicine

VANCOUVER, BC, March 7, 2023 /PRNewswire/ - INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically "metastatic castration resistant prostate cancer" also known as "mCRPC".

Key Points: 
  • VANCOUVER, BC, March 7, 2023 /PRNewswire/ - INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically "metastatic castration resistant prostate cancer" also known as "mCRPC".
  • INITIO received the license from the Canadian Nuclear Safety Commission last week and will begin offering patient treatments after March 15.
  • Any compound which does not bind to cancer tissue is primarily cleared from the body by the kidneys.
  • At present, although Lu-177-PSMA is Health Canada approved and an effective prostate cancer treatment, it is not publicly funded.

China Performs First Cancer Patient Treatments in the Xiamen Humanity Hospital Using Novel Accelerator-based Radiation Oncology Therapy (BNCT)

Retrieved on: 
Monday, February 27, 2023
Software, Research, General Health, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Clinical Trials, Science, Biotechnology, Health, Other Science, Neutron, NMG, Safety, Neck, BNCT, Observation, Patient, Trial of the century, IIT, IRB, PET, Interlocking, BPA, Head, Cancer, CSO, James A. Schlipmann Melanoma Cancer Foundation, Boston Medical Group, Pharmaceutical industry, Accelerator

With this milestone, China has become the second country to master and utilize accelerator BNCT technology.

Key Points: 
  • With this milestone, China has become the second country to master and utilize accelerator BNCT technology.
  • The clinical protocol relied on a full suite of NeuPex AB-BNCT device system and NeuMANTA® Treatment Planning system, boron-containing drug BPA and PET imaging drug F-BPA supplied from Neuboron.
  • These twelve patients were diagnosed with recurrent head and neck, high-grade glioma, and melanoma cancers with traditional cancer therapies exhausted.
  • The clinical study preliminarily not only verifies the safety of the combined treatment of neutron radiation and BPA drug, but also demonstrated good clinical treatment value.

Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help

Retrieved on: 
Wednesday, December 14, 2022
Weight loss, Quality of life, Hypoesthesia, Peripheral neuropathy, Extremities, Erectile dysfunction, Paresthesia, Boston Medical Group, Pain, Telehealth, National Institutes of Health Clinical Center, Growth, Patient, Health insurance, Pharmaceutical industry, Medicine, Tampa Bay

ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live .

Key Points: 
  • ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live .
  • "We're passionate about helping our patients find relief from their symptoms and improve their quality of life," said Spinoso, founder of St. Pete Medical Group.
  • For more information about St. Pete Medical Group and Clearwater Medical Group, or to schedule an appointment, please visit their website at www.stpetemedicalgroup.com or call (727)-354-8744.
  • ABOUT ST PETE MEDICAL GROUP: St. Pete Medical Group's mission is to create a comfortable experience for you.

Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Retrieved on: 
Thursday, October 21, 2021
Aurora, Paragon, Program, Solution, Children's Hospital, Orphan drug, Research, Fibroblast, COL7, Castle Creek, Regenerative medicine, Mayo Clinic, Twitter, Dell Children's Medical Center, Patient, Concha bullosa, Children's Hospital Colorado, FDA, Stanford University, Scar, COL7A1, Boston Medical Group, Dell, LLC, Principal, VII, Degenerative disease, Skin, Friction, Genetic disorder, Trauma, DEB, ClinicalTrials.gov, Pharmaceutical industry

EXTON, Pa., Oct. 21, 2021 /PRNewswire/ -- Castle Creek Biosciences, Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, today announced that the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded the company a $1.825 million research grant over four years (#1R01–FD007289-01). The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
  • The Congressionally-funded Orphan Products Development Grants Program is designed to enhance the development of medical products for patients with rare diseases.
  • RDEB is a progressive, devastatingly painful and debilitating, rare genetic disorder, and one of the most chronic and severe forms of DEB.
  • Castle Creek Biosciences' dabocemagene autoficel (FCX-007, D-Fi) is being developed to address the deficiency of functional type VII collagen protein (COL7) in patients with dystrophic epidermolysis bullosa (DEB).

Boston Medical Group Opens New Location in Orlando, Florida

Retrieved on: 
Thursday, September 19, 2019
Greater Orlando, Altamonte Springs, Florida, Boston Medical Group, Altamonte Springs station, Florida

LAGUNA HILLS, Calif., Sept. 19, 2019 /PRNewswire-PRWeb/ --Boston Medical Group (BMG) of Florida has announced the opening of a new office in Altamonte Springs, Florida.

Key Points: 
  • LAGUNA HILLS, Calif., Sept. 19, 2019 /PRNewswire-PRWeb/ --Boston Medical Group (BMG) of Florida has announced the opening of a new office in Altamonte Springs, Florida.
  • Boston Medical Group will be treating men with these therapies, and more, at their new office located at 106 Boston Ave, Suite 204, Altamonte Springs, FL 32701.
  • Confidential appoinments can be made by calling (800) 337-7555 or visit http://www.BostonMedicalGroup.com
    About Boston Medical Group: Boston Medical Group (BMG) is a global alliance of medical centers sharing research information and treatment methods for male sexual dysfunction.
  • If you would like more information about BMG's treatment offerings, please call Boston Medical Group at (800) 337-7555 or email [email protected]